Hepregen and BioTime, Inc. form Ascendance Biotechnology, Inc. to address the in vitro cell biology market.
Hepregen featured in Nature article
Gary Impey of SCIEX interviews Mann Shoffner about HepatoPac and the new Hepregen/SCIEX co-offering.
Dr. Sangeeta Bhatia wins $250K Heinz Award
Hepregen's technology featured in AltTox.com article.
Dr. Sangeeta Bhatia featured in WIRED article.
Dr. Sangeeta Bhatia featured in MIT article about future MIT entrepreneurs.
Dr. Sangeeta Bhatia, biomedical engineer and professor at MIT, is the recipient of the 2014 $500,000 Lemelson-MIT Prize. Bhatia is recognized for designing and commercializing miniaturized technologies with applications to improve human health. The Lemelson-MIT Prize, celebrating its 20th year, honors outstanding mid-career inventors improving the world through technological invention and demonstrating a commitment to mentorship in science, technology, engineering and mathematics.
August 2014 (MIT News)
Model of Viral Lifecycle Could Help in Finding a Cure for Hepatitis B. Read More
October 2013 (Drug Discovery and Development)
Onyi Irrechukwu, Ph.D. Coculture Systems Increase Sensitivity for Predictive Toxicology Studies. Read More
"Hepregen Gets $500K Grant" – Hepregen receives a $500,000 SBIR Phase 2B grant to further develop its liver model for drug development. Read More
June, 2011 (Life Science Leader)
"Drug Safety — Time For A Great Leap Forward?" Excerpt: Risk depends on knowledge. "Without accurate and predictive information about a drug, risk of 'false negatives' may be high," says Bernadette (Bonnie) Fendrock, president and CEO of Hepregen. Her company is developing a highly sensitive in vitro cellular model for preclinical testing to detect liver-toxicity signals in drug compounds. But Fendrock also sees the need for addressing safety on a wider front. “Although meaningful to each, the safety issue is addressed differently by various constituents: regulatory agencies and internally by scientists. In addition, top levels of management need to provide incentives for increasing safety just as they do for improving the drug pipeline." Read More
March 30, 2011 (Nature International weekly journal of science/nature.com)
"Tissue models: A living system on a chip" Nature 471,661–665 (31 March 2011) Excerpt: For years, scientists have struggled to reconstruct tissues and organs by combining cells and nanotechnology. These devices are now edging from cool concept to practical application. Read More
April 2009 (Drug Discovery News)
"Putting Liver on a Chip" Read More
February 27, 2009 (Cell-Based Assay News)
"Battelle Ventures Spins Out Hepregen with $5M in Funding to Develop 'Microliver' Tox Platform" Read More
January 8, 2008 (Drug Discovery News)
"Honey, I shrunk the liver"
Excerpt: With liver toxicity looming as one of the main reasons pharmaceutical companies pull drugs off the market, the development of a technology to create tiny colonies of living human liver cells that model the full-sized organ should be welcome news to drug discovery and development professionals. MIT researchers recently reported that they had devised just such a technology, and believe their work could allow better screening of new drugs that are potentially harmful to the liver and may reduce the costs associated with their development. Read More